Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users

AIDS and Behavior

Volumn 18, Issue 4, 2014, Pages 740-746

  Reddon, H ^a   Milloy, M J ^a   Simo, A ^a   Montaner, J ^a   Wood, E ^a   Kerr, T ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Discontinuation; Drug use; HIV; Methadone

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; METHADONE; NARCOTIC ANALGESIC AGENT; STREET DRUG;

ADULT; CANADA; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGY; FEMALE; HIV INFECTIONS; HUMAN; KAPLAN MEIER METHOD; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PROGRAM EVALUATION; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANALGESICS, OPIOID; ANTI-HIV AGENTS; CANADA; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PROGRAM EVALUATION; PROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84897381233     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0584-z     Document Type: Article

References (46)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investig N Engl J Med. 1998;338(13):853.
2. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160(5):659-65.
3. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17(1):10-22.
4. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47.
5. Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: associations with race. AIDS Care. 2002;14(5):607-17.
6. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362(9400):2002-11.
7. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 2003;17(5):711.
8. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357.
9. Wood E, Kerr T, Montaner JSG. HIV treatment, injection drug use, and illicit drug policies. Lancet. 2007;370(9581):8-10.
10. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;18(4):255-61.
11. Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE, Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. making it happen The WHO strategy" ("3 by 5"). Addiction. 2006;101(9):1246-53.
12. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1115-23.
13. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165(6):618-23.
14. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656-61.
15. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. 2001;286(22):2857-64.
16. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003;188(8):1164-70.
17. Wood E, Montaner JS, Braitstein P, Yip B, Schechter MT, O'Shaughnessy MV, et al. Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. Int J Drug Pol. 2003;15(2):133-38.
18. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539.
19. Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in vancouver. Antivir Ther. 2004;9(3):407.
20. Wood E, Montaner JS, Bangsberg DR, Tyndall MW, Strathdee SA, O'Shaughnessy MV, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003;17(17):2419-27.
21. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907-13.
22. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy(HAART) adherence: evidence from the MANIF 2000 cohort study. Addiction. 2008;103(11):1828-36.
23. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188-94.
24. Strathdee SA, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12(Suppl A):S71.
25. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139(10):810-6.
26. Nosyk B, Marsh DC, Sun H, Schechter MT, Anis AH. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat. 2010;39(1):22-31.
27. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction. 1994;89(2):203-9.
28. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334(11):701-6.
29. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138(11):923-36.
30. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med. 2009;68(6):1044-9.
31. Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place. 2009;15(3):753-60.
32. Hogg RS, Heath KV, Bangsberg D, Yip BPN, O'Shaughnessy MVMJS. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS. 2002;16(7):1051.
33. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp Clin Trials. 2009;30(5):481-9.
34. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18(4):262-70.
35. Werb D, Kerr T, Marsh D, Li K, Montaner J, Wood E. Effect of methadone treatment on incarceration rates among injection drug users. Eur Addict Res. 2008;14(3):143.
36. Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215-21.
37. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367-87.
38. Novitsky V, Essex M. Using HIV viral load to guide treatment-for- prevention interventions. Curr Opin HIV Aids. 2012;7(2):117-24.
39. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377-81.
40. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117-27.
41. DeBeck K, Kerr T, Li K, Fischer B, Buxton J, Montaner J, et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Can Med Assoc J. 2009;181(9):5.
42. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185-94.
43. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(2):CD002209.
44. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253-63.
45. Johnson T, Fendrich M. Modeling sources of self-report bias in a survey of drug use epidemiology. Ann Epidemiol. 2005;15(5):381-9.
46. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction. 1998;93(8):1191-7.